NCT05301751CompletedPhase 2
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients With Diabetic Macular Edema
Source: ClinicalTrials.gov · Last updated 15 Oct 2025
Brief summary (registry, in English)
This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME). The objectives of this study were to evaluate the safety, tolerability, duration of effect, systemic pharmacokinetic and immunogenicity profiles of ascending doses of AG-73305 administered by intravitreal injection to patients with DME. Pharmacodynamic endpoints (e.g., best-corrected visual acuity \[BCVA\], spectral domain optical coherence tomography \[SD-OCT\], and optical coherence tomography angiography \[OCT-A\]) were evaluated over 6 months post-treatment. The maximum tolerated dose or the highest administered dose was evaluated for future studies.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 20 Mar 2022
- Start date
- 19 May 2022
- Primary completion date
- 28 Sept 2023
- Lead sponsor
- Allgenesis Biotherapeutics Inc.
- Diseases
- Diabetic eye disease
- NCT number
- NCT05301751
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 25
- From 19 May 2022 to the primary completion date, 28 Sept 2023
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any anti-vascular endothelial growth factor (VEGF) treatment in the study eye within 6 to 8 weeks prior to Baseline
- Use of Ozurdex (dexamethasone) within 6 months prior to Baseline or any use of Iluvien (fluocinolone acetonide) in the study eye
- Uncontrolled intraocular pressure (IOP), defined as an IOP \> 25 mmHg, despite anti-glaucoma medications in the study eye at the time of screening or controlled glaucoma that requires management with \> 2 topical hypotensive medications
- Any anti-integrin therapy (e.g., Xiidra) within 60 days before baseline in the study eye
Other illness
- Uncontrolled hypertension with systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg at Screening or Baseline
- Chronic renal disease
- Any active infection in either eye
Lab values
- Uncontrolled diabetes mellitus, defined as hemoglobin A1c \> 12.0% at Screening
Who the study is looking for
- Male or female, 18 years of age or older at the screening visit
- Prior diagnosis of diabetes mellitus (Type 1 or Type 2) as defined by World Health Organization or American Diabetes Association
- Presence of center-involving DME in the study eye with CST ≥ 325 μm
- Visual acuity loss in the study eye attributed to DME with screening and baseline ETDRS BCVA letter score of 20 to 55 (20/400 to 20/80 Snellen equivalent) in the sentinel patients and 35 to 70 (20/200 to 20/40 Snellen equivalent) in the non-sentinel patients
- Cohort 1: Previously treated with an anti-VEGF in the study eye; Cohorts 2, 3, and 4: Previously treated or treatment-naïve to the study eye
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Retina Research Institute of Texas Coordinator of this site? Confirm its status | Abilene | United States | Unknown status |
| Texas Retina Associates Coordinator of this site? Confirm its status | Fort Worth | United States | Unknown status |
| Valley Retina Institute Coordinator of this site? Confirm its status | McAllen | United States | Unknown status |
| Retina Vitreous Associates of Florida Coordinator of this site? Confirm its status | St. Petersburg | United States | Unknown status |
| Strategic Clinical Research Group, LLC Coordinator of this site? Confirm its status | Willow Park | United States | Unknown status |
| Center of Macula and Retina Disease Coordinator of this site? Confirm its status | Winter Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.